ROYALTY PHARMA PLC- CL A (RPRX) Stock News
NASDAQ:RPRX - Nasdaq - GB00BMVP7Y09 - Common Stock - Currency: USD
RPRX Latest News, Press Releases and Analysis
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue...
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2024...
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
2024 Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with potential...
Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of greater than...
Royalty Pharma Announces Dividend Increase
Royalty Pharma Announces Dividend Increase
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the...
3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer
2 Exceptional Dividend Stocks Near 52-Week Lows You Could Regret Not Buying on the Dips
2 Exceptional Dividend Stocks Near 52-Week Lows You Could Regret Not Buying on the Dips
The benchmark stock indexes keep climbing to new heights, but there are plenty of attractive wallflowers at this dance. A couple of overlooked dividend payers offer high yields and reliable dividend payout growth, but you wouldn't know it by looking at their stock prices. Shares of W.P. Carey (NYSE: WPC) and Royalty Pharma (NASDAQ: RPRX) were beaten down to 52-week lows not long ago, and they've only recovered a little.
Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor...
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the Prostate...
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will acquire a synthetic royalty on U.S. sales of Geron Corporation’s (Nasdaq: GERN) RYTELO for $125 million in cash upfront.
Royalty Pharma Reports Third Quarter 2024 Results
Royalty Pharma Reports Third Quarter 2024 Results
Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15%Net cash provided by operating activities of $704 millionCapital Deployment...
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through...
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™
/PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Syndax has entered into a $350 million...
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2024 financial...
Royalty Pharma Declares Fourth Quarter 2024 Dividend
Royalty Pharma Declares Fourth Quarter 2024 Dividend
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the...
